US EditionFDA Begins Phasing Out Certain Animal Testing Practices: commissioner
- The US Food and Drug Administration announced it will phase out requirements for testing monoclonal antibodies and other drugs on animals, citing "more effective, human-relevant methods" to test drugs.
- The bipartisan FDA Modernization Act 2.0, passed in 2022, allows drug sponsors to use alternatives instead of animal studies for licensure.
- The FDA stated that this change marks a "paradigm shift in drug evaluation," aimed at improving drug safety and accelerating the evaluation process.
- This initiative will reduce animal use and lower costs and prices, promising better treatments.
186 Articles
186 Articles
Kudos to the FDA and EPA for planning to phase out animal testing
The U.S. Food and Drug Administration said it plans to phase out animal testing in the development of monoclonal antibody therapies and other drugs with human-relevant methods. (Photo by Adam Gault/Getty Images)As a board-certified family and lifestyle medicine physician in Salt Lake City, I laud both the Food and Drug Administration and the Environmental Protection Agency for separately announcing initiatives last week to start backing off of a…
Donald Trump just forced PETA to praise him with one order that blindsided the Left - Political Animal News
The radical Left spent years calling Donald Trump cruel and heartless. Now even PETA can’t deny what Trump just did for thousands of innocent animals. And Donald Trump just forced PETA to praise him with one order that blindsided the Left. Trump administration finally ends barbaric animal testing that Biden quietly protected President Donald Trump […]
protrumpnews.com
PETA Thanks Trump Administration – FDA Phasing Out Animal Testing
The FDA is replacing “animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods.” According to the FDA, “The FDA’s animal testing requirement will be reduced, refined, or potentially replaced using a range of approaches, including AI-based computational models of toxicity and cell lines and organoid toxicity testing in a laboratory setting (so-called New Approach Methodologies …
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
CollPlant's novel rhCollagen BioInks are an available solution aligned with FDA's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates
Coverage Details
Bias Distribution
- 59% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
